Aeterna Zentaris Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023
Ticker: CSCIF · Form: 20-F · Filed: Mar 27, 2024 · CIK: 1113423
Sentiment: neutral
Topics: Aeterna Zentaris, 20-F Filing, Annual Report, Pharmaceuticals, Financials
TL;DR
<b>Aeterna Zentaris Inc. has submitted its 2023 annual report on Form 20-F, detailing its financial performance and business operations.</b>
AI Summary
Aeterna Zentaris Inc. (CSCIF) filed a Foreign Annual Report (20-F) with the SEC on March 27, 2024. Aeterna Zentaris Inc. filed its 20-F annual report on March 27, 2024, for the fiscal year ending December 31, 2023. The company's principal business is in Pharmaceutical Preparations, SIC code 2834. Aeterna Zentaris Inc. was formerly known as AETERNA LABORATORIES INC, with a name change on May 3, 2000. The filing includes financial data for the fiscal years 2021, 2022, and 2023. The business address and mailing address are both listed as C/O NORTON ROSE FULBRIGHT CANADA LLP, 222 BAY STREET, SUITE 3000, PO BOX 53, TORONTO, A6, M5K 1E7.
Why It Matters
For investors and stakeholders tracking Aeterna Zentaris Inc., this filing contains several important signals. This filing provides investors and stakeholders with a comprehensive overview of the company's financial health and strategic direction for the past fiscal year. As a pharmaceutical preparations company, the 20-F report is crucial for understanding regulatory compliance, product development, and market positioning within the healthcare industry.
Risk Assessment
Risk Level: low — Aeterna Zentaris Inc. shows low risk based on this filing. The filing is a standard annual report (20-F) and does not contain immediate red flags or significant negative developments, indicating a routine disclosure.
Analyst Insight
Monitor future filings for updates on financial performance, product pipeline developments, and any strategic shifts mentioned in the 20-F report.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reported period.)
- 2024-03-27 — Filing Date (Date the 20-F was filed.)
- 2834 — SIC Code (Pharmaceutical Preparations.)
- 001-38064 — SEC File Number (Aeterna Zentaris Inc.'s SEC file number.)
Key Players & Entities
- Aeterna Zentaris Inc. (company) — Filer of the 20-F report.
- AETERNA LABORATORIES INC (company) — Former name of Aeterna Zentaris Inc.
- NORTON ROSE FULBRIGHT CANADA LLP (company) — Address provider for Aeterna Zentaris Inc.
- 2024-03-27 (date) — Filing date of the 20-F report.
- 2023-12-31 (date) — Fiscal year end date for the report.
FAQ
When did Aeterna Zentaris Inc. file this 20-F?
Aeterna Zentaris Inc. filed this Foreign Annual Report (20-F) with the SEC on March 27, 2024.
What is a 20-F filing?
A 20-F is a annual report for foreign private issuers, equivalent to a 10-K but following international reporting standards. This particular 20-F was filed by Aeterna Zentaris Inc. (CSCIF).
Where can I read the original 20-F filing from Aeterna Zentaris Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Aeterna Zentaris Inc..
What are the key takeaways from Aeterna Zentaris Inc.'s 20-F?
Aeterna Zentaris Inc. filed this 20-F on March 27, 2024. Key takeaways: Aeterna Zentaris Inc. filed its 20-F annual report on March 27, 2024, for the fiscal year ending December 31, 2023.. The company's principal business is in Pharmaceutical Preparations, SIC code 2834.. Aeterna Zentaris Inc. was formerly known as AETERNA LABORATORIES INC, with a name change on May 3, 2000..
Is Aeterna Zentaris Inc. a risky investment based on this filing?
Based on this 20-F, Aeterna Zentaris Inc. presents a relatively low-risk profile. The filing is a standard annual report (20-F) and does not contain immediate red flags or significant negative developments, indicating a routine disclosure.
What should investors do after reading Aeterna Zentaris Inc.'s 20-F?
Monitor future filings for updates on financial performance, product pipeline developments, and any strategic shifts mentioned in the 20-F report. The overall sentiment from this filing is neutral.
How does Aeterna Zentaris Inc. compare to its industry peers?
Aeterna Zentaris Inc. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, regulatory oversight, and market competition.
Are there regulatory concerns for Aeterna Zentaris Inc.?
As a foreign private issuer, Aeterna Zentaris Inc. files annual reports on Form 20-F, which are subject to SEC regulations governing disclosures for companies incorporated outside the United States.
Industry Context
Aeterna Zentaris Inc. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, regulatory oversight, and market competition.
Regulatory Implications
As a foreign private issuer, Aeterna Zentaris Inc. files annual reports on Form 20-F, which are subject to SEC regulations governing disclosures for companies incorporated outside the United States.
What Investors Should Do
- Review the full 20-F filing for detailed financial statements and management's discussion and analysis.
- Analyze the company's risk factors section for potential challenges and uncertainties.
- Track future SEC filings for updates on the company's progress and any material events.
Key Dates
- 2024-03-27: Filing of 20-F Annual Report — Provides comprehensive financial and operational data for the fiscal year 2023.
- 2023-12-31: Fiscal Year End — Marks the end of the reporting period covered by the 20-F.
Year-Over-Year Comparison
This filing represents the annual disclosure for the fiscal year 2023, following previous filings which would have covered prior periods.
Filing Stats: 4,520 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2024-03-27 08:05:53
Key Financial Figures
- $1.00 — imum closing bid price of not less than $1.00 per share, as set forth in Nasdaq Listi
- $4.00 — ecurities have a minimum bid price of US$4.00 per share or a minimum closing price of
- $2.00 — r share or a minimum closing price of US$2.00 to US$3.00 per share, with the specific
- $3.00 — a minimum closing price of US$2.00 to US$3.00 per share, with the specific requisite
Filing Documents
- form20-f.htm (20-F) — 3055KB
- ex1-4.htm (EX-1.4) — 4KB
- ex2-2.htm (EX-2.2) — 16KB
- ex4-6.htm (EX-4.6) — 4KB
- ex4-7.htm (EX-4.7) — 1KB
- ex8-1.htm (EX-8.1) — 3KB
- ex11-1.htm (EX-11.1) — 23KB
- ex12-1.htm (EX-12.1) — 18KB
- ex12-2.htm (EX-12.2) — 18KB
- ex13-1.htm (EX-13.1) — 9KB
- ex13-2.htm (EX-13.2) — 9KB
- ex15-1.htm (EX-15.1) — 4KB
- ex15-2.htm (EX-15.2) — 4KB
- ex97-1.htm (EX-97.1) — 56KB
- form20-f_001.jpg (GRAPHIC) — 8KB
- form20-f_002.jpg (GRAPHIC) — 3201KB
- form20-f_003.jpg (GRAPHIC) — 187KB
- ex8-1_001.jpg (GRAPHIC) — 21KB
- ex1-4_001.jpg (GRAPHIC) — 213KB
- ex1-4_002.jpg (GRAPHIC) — 247KB
- ex1-4_003.jpg (GRAPHIC) — 161KB
- ex11-1_001.jpg (GRAPHIC) — 93KB
- ex11-1_002.jpg (GRAPHIC) — 329KB
- ex11-1_003.jpg (GRAPHIC) — 379KB
- ex11-1_004.jpg (GRAPHIC) — 349KB
- ex11-1_005.jpg (GRAPHIC) — 448KB
- ex11-1_006.jpg (GRAPHIC) — 495KB
- ex11-1_007.jpg (GRAPHIC) — 416KB
- ex11-1_008.jpg (GRAPHIC) — 439KB
- ex11-1_009.jpg (GRAPHIC) — 439KB
- ex11-1_010.jpg (GRAPHIC) — 532KB
- ex11-1_011.jpg (GRAPHIC) — 479KB
- ex11-1_012.jpg (GRAPHIC) — 369KB
- ex11-1_013.jpg (GRAPHIC) — 404KB
- ex11-1_014.jpg (GRAPHIC) — 439KB
- ex11-1_015.jpg (GRAPHIC) — 550KB
- ex11-1_016.jpg (GRAPHIC) — 466KB
- ex11-1_017.jpg (GRAPHIC) — 462KB
- ex11-1_018.jpg (GRAPHIC) — 482KB
- ex11-1_019.jpg (GRAPHIC) — 131KB
- ex4-6_001.jpg (GRAPHIC) — 278KB
- ex4-6_002.jpg (GRAPHIC) — 367KB
- ex4-6_003.jpg (GRAPHIC) — 334KB
- ex4-6_004.jpg (GRAPHIC) — 111KB
- ex4-6_005.jpg (GRAPHIC) — 226KB
- ex4-7_001.jpg (GRAPHIC) — 144KB
- 0001493152-24-011401.txt ( ) — 33617KB
- aezs-20231231.xsd (EX-101.SCH) — 104KB
- aezs-20231231_cal.xml (EX-101.CAL) — 112KB
- aezs-20231231_def.xml (EX-101.DEF) — 308KB
- aezs-20231231_lab.xml (EX-101.LAB) — 602KB
- aezs-20231231_pre.xml (EX-101.PRE) — 471KB
- form20-f_htm.xml (XML) — 1856KB
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 118 Item 12.
Description of Securities Other than Equity Securities
Description of Securities Other than Equity Securities A. Debt securities 119 B. Warrants and rights 119 C. Other securities 119 D. American depositary shares 119 PART II Item 13. Defaults, Dividend Arrearages and Delinquencies 120 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 120 Item 15.
Controls and Procedures
Controls and Procedures 120 Item 16A. Audit Committee Financial Expert 121 Item 16B. Code of Ethics 121 Item 16C. Principal Accountant Fees and Services 121 Item 16D. Exemptions from the Listing Standards for Audit Committees 122 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 122 Item 16F. Change in Registrant's Certifying Accountant 122 Item 16G. Corporate Governance 123 Item 16H. Mine Safety Disclosure 123 Item 16I. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 123 Item 16J. Insider Trading Policy 123 Item 16K. Cybersecurity 124 PART III Item 17.
Financial Statements
Financial Statements 124 Item 18.
Financial Statements
Financial Statements 124 Item 19. Exhibits 125 5 PART I Item 1. Identity of Directors, Senior Management and Advisers A. Directors and senior management Not applicable. B. Advisers Not applicable. C. Auditors Not applicable. Item 2. Offer Statistics and Expected Timetable A. Offer statistics Not applicable. B. Method and expected timetable Not applicable. Item 3. Key Information A. (Reserved) B. Capitalization and indebtedness Not applicable. C. Reasons for the offer and use of proceeds Not applicable. D. Risk factors An investment in our securities involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this Annual Report, before making an investment decision. If any of the following risks actually occur, our business, prospects, financial condition or results of operations could be materially, adversely affected by any of these risks. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned below. Forward-looking in the documents incorporated by reference are based on information available to us as of the date of each such document. We undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, other than as required by applicable law. 6 Risks Relating